Literature DB >> 22239588

Cognitive behavioral therapy in prodromal psychosis.

Jean Addington1, Catherine Marshall, Paul French.   

Abstract

There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.

Entities:  

Mesh:

Year:  2012        PMID: 22239588      PMCID: PMC4356485          DOI: 10.2174/138161212799316082

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  55 in total

Review 1.  Ethics and early intervention in psychosis: keeping up the pace and staying in step.

Authors:  P D McGorry; A Yung; L Phillips
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

Review 2.  Psychosis treatment prior to psychosis onset: ethical issues.

Authors:  T H McGlashan
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

3.  Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation.

Authors:  M Birchwood; J Smith; F Macmillan; B Hogg; R Prasad; C Harvey; S Bering
Journal:  Psychol Med       Date:  1989-08       Impact factor: 7.723

4.  A scaled version of the General Health Questionnaire.

Authors:  D P Goldberg; V F Hillier
Journal:  Psychol Med       Date:  1979-02       Impact factor: 7.723

Review 5.  Cognitive-behavioral therapy for medication-resistant symptoms.

Authors:  P A Garety; D Fowler; E Kuipers
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

6.  Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy.

Authors:  S Pilling; P Bebbington; E Kuipers; P Garety; J Geddes; G Orbach; C Morgan
Journal:  Psychol Med       Date:  2002-07       Impact factor: 7.723

7.  Self-experienced vulnerability, prodromal symptoms and coping strategies preceding schizophrenic and depressive relapses.

Authors:  Andreas Bechdolf; Frauke Schultze-Lutter; Joachim Klosterkötter
Journal:  Eur Psychiatry       Date:  2002-11       Impact factor: 5.361

8.  Cognitive--behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial.

Authors:  Philippa A Garety; David G Fowler; Daniel Freeman; Paul Bebbington; Graham Dunn; Elizabeth Kuipers
Journal:  Br J Psychiatry       Date:  2008-06       Impact factor: 9.319

Review 9.  The concept of basic symptoms in schizophrenic and schizoaffective psychoses.

Authors:  G Huber; G Gross
Journal:  Recenti Prog Med       Date:  1989-12

10.  Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics.

Authors:  Lisa J Phillips; Barnaby Nelson; Hok Pan Yuen; Shona M Francey; Magenta Simmons; Carrie Stanford; Margaret Ross; Daniel Kelly; Kathryn Baker; Philippe Conus; Paul Amminger; Francois Trumpler; Yang Yun; Michelle Lim; Catharine McNab; Alison R Yung; Patrick D McGorry
Journal:  Aust N Z J Psychiatry       Date:  2009-09       Impact factor: 5.744

View more
  1 in total

1.  Stress reactivity as a putative mechanism linking childhood trauma with clinical outcomes in individuals at ultra-high-risk for psychosis: Findings from the EU-GEI High Risk Study.

Authors:  I Paetzold; I Myin-Germeys; A Schick; B Nelson; E Velthorst; F Schirmbeck; J van Os; C Morgan; J Hartmann; M van der Gaag; L de Haan; L Valmaggia; P McGuire; M Kempton; U Reininghaus
Journal:  Epidemiol Psychiatr Sci       Date:  2021-05-28       Impact factor: 6.892

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.